FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint
22. Juni 2023 08:42 ET
|
Concerned Shareholders of Company MindMed
FCM Won the Majority of Retail Shareholders’ Vote and Thanks Them for Their Strong Support FCM Exhorts Institutions to Live Up to Touted Social Investment Goals and Closely Monitor...
FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors
15. Juni 2023 16:23 ET
|
Concerned Shareholders of Company MindMed
FCM Believes MindMed Is Threatening to Violate NASDAQ Requirements Imperiling MindMed’s Listing and Future Liquidity for Shareholders Failure to Satisfy Quorum Requirement at Annual...
FCM Calls for Socially Responsible Investors to Vote for Change at MindMed
09. Juni 2023 16:17 ET
|
Concerned Shareholders of Company MindMed
Believes Socially Responsible Investment Principles Support FCM’s Plan to Bring MM-120 To the Market in 2026 to Benefit Millions with Mental Health Disorders FCM Directors Will Put in Place Strict...
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
07. Juni 2023 08:07 ET
|
Concerned Shareholders of Company MindMed
FCM Confident in Ability to Start MM-120 Phase III in 2023 and Obtain FDA Approval In 2026 Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period For Selling Shares Until June 15, 2026 ...
ISS Appears to Rely on MindMed's False and Misleading Statements to Justify the Company's Abysmal Performance; Seemingly Ignores MindMed's Apparent Disregard of Patient Safety
05. Juni 2023 06:19 ET
|
Concerned Shareholders of Company MindMed
ISS Dismissed 47% Stock Price Drop Following September 2022 Financing as In Line with “Sectoral Trends”, in a Baffling Lack of Critical Analysis and Seemingly in Opposition to the Factual...
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
02. Juni 2023 16:17 ET
|
Concerned Shareholders of Company MindMed
FCM Predicts That the Psychedelic Revolution Will Begin with the FDA’s Likely Groundbreaking Approval of the Drug MDMA, Which is Expected to Occur in the Second Half of 2024 Reiterates that MindMed...
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
30. Mai 2023 16:17 ET
|
Concerned Shareholders of Company MindMed
FCM Director Candidates, including Dr. Freeman, and Mr. Jake Freeman, Commit to Not Selling Any of Their MindMed Shares Until June 15, 2025 FCM and its Nominees Stand Behind Their Plan to Drive Value...